Menu
 

CHANGING THE WAY
THE WORLD BREATHES.

TRY our products Today.

Select a product below to learn more and purchase online.

About

Latest Rhinomed NEWS.

  • APPENDIX 4E PRELIMINARY FINAL REPORT

    Rhinomed (ASX:RNO) a leader in nasal respiratory technology, today released the Appendix 4E Preliminary Final Report

    Read More
  • BUSINESS UPDATE – JUNE QUARTER CASH FLOW REPORT

    Rhinomed (ASX:RNO) a leader in nasal respiratory technology, today announced a pivotal year of growth and milestone achievement. The company can report record recognised revenues for FY18 Q4 of $874k - a 71% increase over FY18 Q3 and totalling $2.13m for the full FY18, up 24% on FY17.

    Read More
  • RNO & US BASED COLUMBIA CARE TO DEVELOP NASALLY DELIVERED DOSE CONTROLLED CANNABIS BASED MEDICINES

    RNO is pleased to advise investors that it has signed a non-binding term sheet with Columbia Care LLC to license RNO's nasal platform for the delivery of medical cannabis and cannabinoid compounds, analogues and derivatives.

    Read More